These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 2138378

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Therapy of osteoporosis using the ADFR schedule (especially with parathyroid hormone and etidronate)].
    Ziegler R.
    Internist (Berl); 1991 Feb; 32(2):76-9. PubMed ID: 1903362
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Treatment of postmenopausal osteoporotic women with parathyroid hormone 1-84 for 18 months increases cancellous bone formation and improves cancellous architecture: a study of iliac crest biopsies using histomorphometry and micro computed tomography.
    Fox J, Miller MA, Recker RR, Bare SP, Smith SY, Moreau I.
    J Musculoskelet Neuronal Interact; 2005 Feb; 5(4):356-7. PubMed ID: 16340137
    [No Abstract] [Full Text] [Related]

  • 7. Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84.
    Recker RR, Bare SP, Smith SY, Varela A, Miller MA, Morris SA, Fox J.
    Bone; 2009 Jan; 44(1):113-9. PubMed ID: 18983947
    [Abstract] [Full Text] [Related]

  • 8. Bone histomorphometry in the pathophysiological evaluation of primary and secondary osteoporosis and various treatment modalities.
    Steiniche T.
    APMIS Suppl; 1995 Jan; 51():1-44. PubMed ID: 7669370
    [Abstract] [Full Text] [Related]

  • 9. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal.
    Cosman F, Nieves J, Woelfert L, Formica C, Gordon S, Shen V, Lindsay R.
    J Bone Miner Res; 2001 May; 16(5):925-31. PubMed ID: 11341338
    [Abstract] [Full Text] [Related]

  • 10. A small dose of human parathyroid hormone(1-34) increased bone mass in the lumbar vertebrae in patients with senile osteoporosis.
    Sone T, Fukunaga M, Ono S, Nishiyama T.
    Miner Electrolyte Metab; 1995 May; 21(1-3):232-5. PubMed ID: 7565456
    [Abstract] [Full Text] [Related]

  • 11. [Loss of trabecular bone strength and bone quality after 5 years of fluoride therapy for osteoporosis].
    Søgaard CH, Mosekilde L, Richards A, Mosekilde L.
    Ugeskr Laeger; 1995 Apr 03; 157(14):2004-8. PubMed ID: 7740640
    [Abstract] [Full Text] [Related]

  • 12. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis.
    Dalle Carbonare L, Arlot ME, Chavassieux PM, Roux JP, Portero NR, Meunier PJ.
    J Bone Miner Res; 2001 Jan 03; 16(1):97-103. PubMed ID: 11149495
    [Abstract] [Full Text] [Related]

  • 13. Results of a stimulatory therapy of low bone metabolism in osteoporosis with (1-38)hPTH and diphosphonate EHDP. Protocol of study I, osteoporosis trial Hannover.
    Hesch RD, Heck J, Delling G, Keck E, Reeve J, Canzler H, Schober O, Harms H, Rittinghaus EF.
    Klin Wochenschr; 1988 Oct 03; 66(19):976-84. PubMed ID: 3141672
    [Abstract] [Full Text] [Related]

  • 14. Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure.
    Compston JE.
    Bone; 2007 Jun 03; 40(6):1447-52. PubMed ID: 17045858
    [Abstract] [Full Text] [Related]

  • 15. Cyclic therapy of osteoporosis with neutral phosphate and brief, high-dose pulses of etidronate.
    Mallette LE, LeBlanc AD, Pool JL, Mechanick JI.
    J Bone Miner Res; 1989 Apr 03; 4(2):143-8. PubMed ID: 2499164
    [Abstract] [Full Text] [Related]

  • 16. Partial maintenance of extra cancellous bone mass by antiresorptive agents after discontinuation of human parathyroid hormone (1-38) in right hindlimb immobilized rats.
    Ma Y, Jee WS, Chen Y, Gasser J, Ke HZ, Li XJ, Kimmel DB.
    J Bone Miner Res; 1995 Nov 03; 10(11):1726-34. PubMed ID: 8592950
    [Abstract] [Full Text] [Related]

  • 17. Recombinant parathyroid hormone in the management of osteoporosis.
    Compston J.
    Calcif Tissue Int; 2005 Aug 03; 77(2):65-71. PubMed ID: 16059774
    [No Abstract] [Full Text] [Related]

  • 18. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial.
    Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD.
    J Bone Miner Res; 2000 May 03; 15(5):944-51. PubMed ID: 10804025
    [Abstract] [Full Text] [Related]

  • 19. Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium.
    Lindsay R, Zhou H, Cosman F, Nieves J, Dempster DW, Hodsman AB.
    J Bone Miner Res; 2007 Apr 03; 22(4):495-502. PubMed ID: 17227219
    [Abstract] [Full Text] [Related]

  • 20. Effect and safety of intermittent weekly administration of human parathyroid hormone 1-34 in patients with primary osteoporosis evaluated by histomorphometry and microstructural analysis of iliac trabecular bone before and after 1 year of treatment.
    Miki T, Nakatsuka K, Naka H, Masaki H, Imanishi Y, Ito M, Inaba M, Morii H, Nishizawa Y.
    J Bone Miner Metab; 2004 Apr 03; 22(6):569-76. PubMed ID: 15490267
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.